Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002155 · ClinicalTrials.gov registry record · NA

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

A NA study of HIV Infections, sponsored by Merck Sharp & Dohme.

Completed
Registry status
NA
Development phase
600
Enrollment target
1
Study location

NCT00002155: Completed NA study of HIV Infections, sponsored by Merck Sharp & Dohme.

NCT00002155 is a NA study of HIV Infections that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 600 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002155, a NA study of HIV Infections, has completed, sponsored by Merck Sharp & Dohme.

COMPLETED
Registry status
NA
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT/3TC.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • DRUG Lamivudine
  • DRUG Indinavir sulfate

Study Locations (1)

New Jersey

  • Merck & Co Inc - Whitehouse Station

Trial Details

FieldValue
Enrollment Target 600 participants
Phase NA
Merck Sharp & Dohme

558 total trials

What the finished NCT00002155 record still lists

NCT00002155 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% higher).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.

NCT00002155 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002155 about?

NCT00002155 is a clinical study titled "A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC". To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT/3TC.

What is the current status of trial NCT00002155?

This trial is currently completed. It is a NA study. The enrollment target is 600 participants.

What conditions does trial NCT00002155 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002155?

The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Indinavir sulfate (DRUG).

Who is sponsoring clinical trial NCT00002155?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002155 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002155's enrollment target sits among peer trials

600 51st of 542 higher than 490 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Related registry views

Source: ClinicalTrials.gov NCT00002155, the US trial registry maintained by the National Library of Medicine. NCT00002155 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.